Meta Information
ID:sulbutiamine
Name:
Schema Version:2.4_uniform_evidence_2026_06_18
Created
2026-05-21T22:30:00Z
Model
phase-a-upgrade-claude-sonnet-4.6
Interactions
Target id:
/dietary/high-fat-meal
Target name:
Meal Containing Fats
Severity:
moderate
Interaction type:
requirement
Nature:
temporal
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Sulbutiamine is a lipophilic (fat-soluble) compound, and its absorption from the gut is significantly enhanced when consumed with dietary fats.
Actionable advice:
Sulbutiamine is best taken with a meal that includes a source of healthy fats like avocado, nuts, or olive oil.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Exact phrase from label:
These modifications increase the lipophilic characteristic of this derivative compared to thiamine.
Label source:
Primary literature: https://pmc.ncbi.nlm.nih.gov/articles/PMC7210561/
Action type:
informational_none
Target id:
/circadian/sleep
Target name:
Going to Sleep
Severity:
moderate
Interaction type:
adverse
Nature:
temporal
Temporal spacing:
Hours before target:
8
Hours after target:
null
Description:
Sulbutiamine often has stimulating effects on the central nervous system which can interfere with sleep onset, duration, and quality.
Actionable advice:
A dose is best taken in the morning or early afternoon, at least 8 hours before the planned bedtime.
Validation status:
validated_via_pubmed
Evidence tier:
tier_b
Evidence basis:
pubmed_abstract_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Sulbutiamin induced the following modifications: (1) In the EEG activities: increase in occurrence of fast rhythms (over 28 c/sec) during waking and also during slow sleep (SS) in which their amplitude doubled.
Label source:
PubMed: Revue d'electroencephalographie et de neurophysiologie clinique (1982)
Source url:
Exact phrase from label:
In vigilance organization: waking was enhanced all along the 24 h recording and SS was reorganized (particularly at night), mostly light sleep: large decrease in stage 2 duration, increase in stage 1.
Label source:
PubMed: Revue d'electroencephalographie et de neurophysiologie clinique (1982)
Source url:
Exact phrase from label:
This study demonstrated the clear action of Sulbutiamin upon the mechanisms regulating waking and light sleep.
Label source:
PubMed: Revue d'electroencephalographie et de neurophysiologie clinique (1982)
Action type:
separate
Target id:
/class/stimulants
Target name:
Stimulant Medications
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Sulbutiamine can exert its own stimulating effects and may potentiate the action of other stimulants, increasing the risk of overstimulation, anxiety, jitteriness, and increased heart rate.
Actionable advice:
Prescription stimulants (e.g., for ADHD) are best avoided, or used with extreme caution under medical supervision.
Validation status:
validated_via_pubmed
Evidence tier:
tier_b
Evidence basis:
pubmed_abstract_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
This may indicate that sulbutiamine was intentionally administered for its ergogenic and mild stimulating properties.
Label source:
PubMed: Drug testing and analysis (2010)
Source url:
Exact phrase from label:
Ingredients of most concern detected include stimulants: demelverine, 1,5-dimethylhexylamine, 1,3-dimethylhexylamine, N-phenethyl dimethylamine, halostachine, higenamine, noopept, β-PEA, vinpocetine, sulbutiamine; and hordenine, currently on the FDA advisory list.
Label source:
PubMed: Clinical toxicology (Philadelphia, Pa.) (2020)
Action type:
avoid
Target id:
/condition/bipolar-disorder
Target name:
Bipolar Disorder
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
The stimulating and mood-elevating properties of sulbutiamine have been documented in case reports to trigger manic or hypomanic episodes in individuals with bipolar disorder.
Actionable advice:
This should be strictly avoided with a diagnosis of, or predisposition to, bipolar disorder.
Validation status:
validated_via_pubmed
Evidence tier:
tier_b
Evidence basis:
pubmed_abstract_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
A case of a patient with bipolar disorder with a history of hospitalizations and addiction to sulbutiamine is presented.
Label source:
PubMed: The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry (2006)
Source url:
Exact phrase from label:
Furthermore, the safety data shows that both treatment groups were comparable and in particular that sulbutiamine had not induced any inappropriate behaviour, including suicide attempts, or mania.
Label source:
PubMed: L'Encephale (2000)
Action type:
avoid
Target id:
/intervention/sulbutiamine-chronic-use
Target name:
Continuous Daily Use of Sulbutiamine
Severity:
moderate
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Continuous daily administration of sulbutiamine frequently leads to rapid pharmacological tolerance, where its noticeable psychoactive effects (stimulation, mood enhancement) diminish or disappear.
Actionable advice:
To maintain effectiveness, cycle sulbutiamine by using it only on an as-needed basis or a few times per week.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
While daily use can result in tolerance and paradoxical drowsiness, increasing the dose is strongly discouraged
Label source:
Primary literature: https://en.wikipedia.org/wiki/Sulbutiamine
Action type:
informational_none
Target id:
/circadian/wake
Target name:
Waking Up
Severity:
minor
Interaction type:
synergistic
Nature:
temporal
Temporal spacing:
Hours before target:
null
Hours after target:
4
Description:
Taking sulbutiamine in the morning aligns its energizing effects with the body's natural circadian rhythm for wakefulness, potentially improving focus and combating fatigue during the day.
Actionable advice:
Sulbutiamine is generally best taken within the first few hours of waking for optimal daytime effects.
Validation status:
validated_via_pubmed
Evidence tier:
tier_b
Evidence basis:
pubmed_abstract_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
waking was enhanced all along the 24 h recording and SS was reorganized (particularly at night), mostly light sleep: large decrease in stage 2 duration, increase in stage 1.
Label source:
PubMed: Revue d'electroencephalographie et de neurophysiologie clinique (1982)
Source url:
Exact phrase from label:
This study demonstrated the clear action of Sulbutiamin upon the mechanisms regulating waking and light sleep.
Label source:
PubMed: Revue d'electroencephalographie et de neurophysiologie clinique (1982)
Action type:
informational_none
Target id:
/class/dopaminergic-agents
Target name:
Dopaminergic Medications
Severity:
minor
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Sulbutiamine may increase the density of dopamine D1 receptors in the brain, which could theoretically alter the effects of medications that act on the dopamine system (e.g., L-DOPA, dopamine agonists).
Actionable advice:
This is best used with caution, and it is worth talking to a physician when combining it with dopaminergic medications.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Exact phrase from label:
after administering this molecule to rats for 5 days, there was a significant increase in the density of dopamine D1 receptor binding sites in prefrontal and anterior cingulate cortex (+26% and +34%, respectively)
Label source:
Primary literature: https://pmc.ncbi.nlm.nih.gov/articles/PMC7210561/
Action type:
informational_none
Target id:
/class/cholinesterase-inhibitors
Target name:
Cholinesterase Inhibitors
Severity:
minor
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Some evidence suggests sulbutiamine may enhance cholinergic activity. Combining it with cholinesterase inhibitors (e.g., Huperzine A, galantamine) could theoretically increase the risk of cholinergic side effects like headaches or digestive upset.
Actionable advice:
It is worth watching out for side effects if combining with supplements or drugs that inhibit cholinesterase.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Exact phrase from label:
Chronic administration of moderate to high doses of sulbutiamine to BALB/c mice increased sodium-dependent high affinity choline uptake by 10% in hippocampal neurons
Label source:
Primary literature: https://pmc.ncbi.nlm.nih.gov/articles/PMC7210561/
Action type:
monitor
Target id:
/class/diuretics
Target name:
Diuretics (Water Pills)
Severity:
minor
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Diuretics, particularly loop diuretics, increase the urinary excretion of thiamine (Vitamin B1). Chronic use may increase the body's overall thiamine requirement, potentially impacting the baseline upon which sulbutiamine acts.
Actionable advice:
If using diuretics long-term, discuss your overall thiamine status with your doctor.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
patients using diuretics have an increased urinary excretion of thiamine and thus are at a higher risk for developing thiamine deficiency.
Label source:
Primary literature: https://pubmed.ncbi.nlm.nih.gov/17673878/
Action type:
informational_none
Target id:
/condition/pregnancy
Target name:
Pregnancy
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
The safety and effects of sulbutiamine on fetal development have not been studied in humans.
Actionable advice:
This should be strictly avoided during pregnancy due to a lack of safety data.
Validation status:
anecdotal
Evidence tier:
tier_d
Evidence basis:
anecdotal_summary
Evidence anchors:
Exact phrase from label:
There is not enough reliable information about the safety of taking sulbutiamine if you are pregnant or breast feeding.
Label source:
Anecdotal: WebMD
Action type:
avoid
Target id:
/condition/lactation
Target name:
Breastfeeding (Lactation)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
It is not known whether sulbutiamine or its metabolites are excreted into human breast milk or what effects they might have on a nursing infant.
Actionable advice:
This should be strictly avoided while breastfeeding due to a lack of safety data.
Validation status:
anecdotal
Evidence tier:
tier_d
Evidence basis:
anecdotal_summary
Evidence anchors:
Exact phrase from label:
There is not enough reliable information about the safety of taking sulbutiamine if you are pregnant or breast feeding.
Label source:
Anecdotal: WebMD
Action type:
avoid